drugset / Trial / NCT03477175

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

NCT03477175

Phase 2 Completed 40 enrolled Eisai Inc. Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

Timeline

Start
2018-08-16
Primary completion
2023-12-21
Completion
2023-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule Oral
Background Sorafenib Small molecule

Indications